Journal
DRUG DISCOVERY TODAY
Volume 25, Issue 7, Pages 1198-1205Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2020.04.008
Keywords
-
Categories
Ask authors/readers for more resources
Wild-type and genetically engineered oncolytic viruses (OVs) represent powerful therapeutic agents in cancer immunotherapy. Several OV species are in clinical trials for cancer treatment. Preclinical and clinical trials revealed several issues related to OV therapy in terms of viral delivery, spread, antiviral immune response, and tumor resistance. Here, we suggest some promising computational strategies that can overcome these issues. The strategies include predicting and prioritizing tumor-homing peptides, anticancer peptides, neoantigens, and miRNA response elements in the viral genome. The combination of computational approaches with genetic engineering could enhance the safety, delivery, oncolysis, and antitumor immune responses of OVs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available